Lakefront Biotherapeutics (LKFT) Cash from Discontinued Operations (2021 - 2022)
Lakefront Biotherapeutics (LKFT) posted quarterly Cash from Discontinued Operations of 70517888.23 for Q1 2022, up 48.87% year-on-year from 47367415.25 in Q1 2021, and up 48.87% on a QoQ basis from 137930299.26 in Q1 2021.
Lakefront Biotherapeutics (LKFT) Cash from Discontinued Operations (2021 - 2022) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Cash from Discontinued Operations for 2 consecutive years, with 70517888.23 the latest figure, recorded in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 1.86 Bn | -1.53 Bn | 1.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -70.52 Mn |
| Mar 31, 2022 | -70.52 Mn |
| Mar 31, 2021 | -137.93 Mn |
| Mar 31, 2021 | -137.93 Mn |